Med by Cell Press

New resource in Med by Cell Press outlines a new "theranostic" methodology that enables real-time ex vivo lung assessment and rehabilitation across a variety of lung injuries to help increase clinical utilization of donor lungs https://lnkd.in/eqkQqgkS There is a significant shortage of donor lungs for transplantation, with approximately 80% deemed unsuitable, often due to injury. Cross-circulation, an advanced ex vivo lung perfusion technique, has been shown to rehabilitate injured donor lungs. Key findings include the successful recovery of lungs with various injuries, the use of advanced imaging and assays for real-time assessment, and the delivery of therapeutic modalities including bronchoalveolar lavage and cells/organoids. Ultimately, this approach could increase the number of viable lungs for transplant and reduce mortality among patients on the waitlist. Meghan Pinezich, PhD ? John D. O’Neill ? Brandon A. Guenthart, MD, FACS ? Jinho Kim ? Olaia F. Vila, PhD. ? Stephen P. Ma ? Ya-Wen Chen ? Ahmed Hozain, M.D. ? Aravind Krishnan ? Moeed Fawad ? Katherine M. Cunningham ? Holly Wobma ? Julie Van Hassel ? Hans-Willem Snoeck ? Matthew Bacchetta ? Gordana Vunjak-Novakovic Columbia University Stanford University Stevens Institute of Technology Columbia University Irving Medical Center Vanderbilt University #LungTransplant #OrganDonors #ExVivoPerfusion #CrossCirculation #Theranostics #LungRehabilitation #OrganRecovery

Online Now: Theranostic methodology for ex?vivo donor lung rehabilitation https://dlvr.it/TJnTWn

Online Now: Early-warning signals and the role of H9N2 in the spillover of avian influenza viruses https://dlvr.it/TJl5nt

New research in Med by Cell Press examined the epidemiological patterns of avian influenza virus (AIV) spillover, emphasizing the role of H9N2 in facilitating this process https://lnkd.in/e7DPxMQi The analysis revealed that internal genes from 12 key H9N2 strains help reduce the species barrier between poultry and humans, increasing the potential for AIV spillover. Due to H9N2's low pathogenicity, it has often been overlooked in vaccination programs, resulting in a lack of targeted vaccines. The study suggests that lowering the prevalence of H9N2 is essential for mitigating spillover risks, as the expansion of AIV host ranges and increasing prevalence in human-contacted hosts pose emerging threats to public health. #AvianInfluenza #AIV #H9N2 #PublicHealth #Epidemiology #PandemicPreparedness #ZoonoticDiseases #DiseasePrevention #OneHealth #Biosecurity #VirusSpillover #GlobalHealth

Check out the March issue of Med by Cell Press: https://hubs.li/Q03cLxjc0 On the cover: Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system. In this issue of Med, Protopapa et al. describe a case of recurrent late-onset neutropenia in a MS patient treated first with ocrelizumab and then switched to ofatumumab, which led to infections and hospitalization. This case highlights the need for careful monitoring of patients on B cell therapies. Additionally, Ladakis et al. found that primary bile acid metabolites in serum can predict brain and retinal atrophy in MS patients. A randomized clinical trial also indicated that bile acid supplementation was safe and resulted in changes to peripheral immune cells and gut microbiota in individuals with progressive MS. Cover image: Viaframe via Stone/Getty Images.

Online Now: Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study https://dlvr.it/TJf7JB

New in Med by Cell Press: A phase 2 clinical study explores the efficacy of disitamab vedotin (DV), a HER2-targeting antibody-drug conjugate, in patients with HER2-negative and HER2-low metastatic urothelial carcinoma (mUC) https://lnkd.in/eGiAXJe7 mUC has a poor prognosis and limited treatment options, with HER2-targeting antibody-drug conjugate (ADCs) showing promise in this context. However, only about 6.7% to 37.5% of patients with mUC are HER2-positive. In the current study, researchers found that DV was generally well tolerated and produced promising anti-tumor activity in HER2-negative and HER2-low mUC, with an objective response rate (ORR) of 31.6% overall and 46.2% in the HER2 IHC 1+ population. #MetastaticUrothelialCarcinoma #mUC #HER2 #DisitamabVedotin #AntibodyDrugConjugates #CancerResearch #Oncology #ClinicalTrials

Online Now: Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors https://dlvr.it/TJcxFK

Our March issue is online! https://lnkd.in/edmuiDBF? Read about Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease - an Article from Pavan Bhargava & colleagues? https://lnkd.in/eRjV34FW Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study – an Article from Zuoyi Jiao (Lanzhou University Second Hospital) & colleagues https://lnkd.in/eFXudn8S Arab founder variants: Contributions to clinical genomics and precision medicine – an Article from Fowzan Alkuraya & colleagues https://lnkd.in/ehV7rVNg Dexmedetomidine decreases cerebral hyperperfusion incidence following carotid stenting: A double-blind, randomized controlled trial - an Article from Daqing Ma (Imperial College London and Zhejiang University School of Medicine), Tianxiao Li, Jiaqiang Zhang (People’s Hospital of Zhengzhou University), & colleagues https://lnkd.in/gZtDiX_4 And more! On the cover: Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system. In this issue of Med, Maria Protopapa et al. describe a case of recurrent late-onset neutropenia in a MS patient treated first with ocrelizumab and then switched to ofatumumab, which led to infections and hospitalization. This case highlights the need for careful monitoring of patients on B cell therapies. Additionally, Ladakis et al. found that primary bile acid metabolites in serum can predict brain and retinal atrophy in MS patients. A randomized clinical trial also indicated that bile acid supplementation was safe and resulted in changes to peripheral immune cells and gut microbiota in individuals with progressive MS. Cover image: Viaframe via Stone/Getty Images. https://lnkd.in/ewURrwNr #MultipleSclerosis #MS #AutoimmuneDisease #Ocrelizumab #Ofatumumab #Neutropenia #ClinicalTrials #Neurodegeneration #BileAcidMetabolites #GutMicrobiota